During the week of April 14th, the Healthcare Distribution Alliance (HDA) held a free Distribution Management Webinar Series to present some of the sessions that were set up for this years 2020 HDA Distribution Management Conference but canceled due to COVID-19. The series of 9 webinars informed individuals and presented them to a wide variety of topics online instead of in-person, as the DMC was canceled due to COVID-19. These webinars raised some extremely fascinating concepts and raised some excellent points on the present struggles the industry is facing due to the virus. A long list of topics including a DSCSA FDA Activity Update, Saleable Returns Verification Industry Update and a Controlled Substance Legal Panel were provided.
By having ARCOS Reporting within Blue Links Pharmaceutical Distribution system, Blue Link consumers are able to easily supply accurate details about the movement of illegal drugs throughout the supply chain, and immediately offer the DEA and other governing companies with the electronic documentation that is needed to do service and operate within the pharmaceutical area.
These HDA Webinars are a very valuable tool, and a great method to keep up to date and informed on essential elements of the market, and will be offered online for your viewing pleasure on April 24th, 2020. Plus, if youre interested in learning more, you can browse their site for additional webinars that are taking location throughout the first week of May.
As everybody in the market understands, there are several and essential aspects to keep an eye on as changes produced by the infection entered into result, so it is good to be notified on those by a market professional. So, with the HDA offering the chance, it was certainly beneficial to participate.
The HDA Webinars gave an update on the potential changes to the schedule of enforcement of Verification of Saleable Returns to the DSCSA– which is November by the way– and introduced some important info on importing pharmaceuticals and rules that might be set in location for importing to Canada from the United States. These are just a little sample of topics discussed.
Blue Links pharmaceutical distribution software helps your company reduce manual work, automate processes, and remain certified with industry policies so that you can concentrate on what really matters: growing your organisation.
Taking a step far from the HDA, we at Blue Link have some information to share with you all regarding ARCOS Reporting. ARCOS, or Automation of Reports and Consolidated Orders System, is a drug-monitoring system that was established by the Drug Enforcement Administration. ARCOS allows the government to keep an eye on the motion of controlled substances from making through point of sale. This is something that is well understood in the pharmaceutical market and is an essential part of Blue Link ERPs Pharma Application.
As Blue Link continues to grow, we develop new functions for our software application based on current and future trends within the pharmaceutical market, as well as by learning from our knowledgeable consumer base. It is crucial that we not only take a look at existing trends, but that we likewise aim to the future, so that we are always one action ahead, and are constantly able to offer the best and most feature-rich software to our consumers.
Throughout the week of April 14th, the Healthcare Distribution Alliance (HDA) held a free Distribution Management Webinar Series to provide some of the sessions that were set up for this years 2020 HDA Distribution Management Conference however canceled due to COVID-19. These webinars brought up some very interesting ideas and raised some very great points on the present has a hard time the industry is facing due to the virus. A long list of subjects consisting of a DSCSA FDA Activity Update, Saleable Returns Verification Industry Update and a Controlled Substance Legal Panel were presented.
All controlled substances in Schedules I and II and all narcotic controlled substances in Schedule III must be reported to the DEA, who need to receive the report by the 15th of the month otherwise a company can be flagged as failure to report. This reporting provides the DEA a much better insight into which compounds are going where, and how each company is handling its item.